Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;18(1):39-47.
doi: 10.5114/wo.2014.40782. Epub 2014 Feb 28.

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

Ying Liu  1 , Shuhua He  2 , Yi Ding  3 , Jing Huang  3 , YuQing Zhang  3 , Longhua Chen  3
Affiliations

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

Ying Liu et al. Contemp Oncol (Pozn). 2014.

Abstract

Several randomized controlled clinical trials have compared therapy with or without thalidomide in the treatment of advanced non-small cell lung cancer (NSCLC). However, these studies did not produce consistent results. We carried out a meta-analysis to determine the efficacy and safety of thalidomide-based therapy in patients with advanced NSCLC. For this meta-analysis, we selected randomized clinical trials that compared thalidomide in combination with other therapy or other therapy alone in patients with advanced NSCLC. The outcomes included median overall survival (OS), one- and two-year survival, tumor response, and toxicities. Hazard ratios (HRs) or risk ratios (RRs) were reported with 95% confidence intervals (CIs). A total of 5 eligible trials were included for the meta-analysis, with 729 patients in the thalidomide group and 711 patients in the control group. Compared with non-thalidomide-based therapy, patients receiving thalidomide plus other therapy did not differ significantly in terms of one- and two-year survival or tumor response (RR = 1.32, 95% CI: 0.66-2.63, p = 0.43; RR = 1.22, 95% CI: 0.48-3.11, p = 0.68; RR = 1.05, 95% CI: 0.92-1.19, p = 0.51, respectively). However, thalidomide-based therapy induced more grade 3-4 dizziness and constipation (RR = 2.05, 95% CI: 1.10-3.81, p = 0.02; RR = 4.78, 95% CI: 1.84-12.38, p = 0.001, respectively). The addition of thalidomide to other therapy did not improve survival and tumor response in patients with advanced NSCLC, and thalidomide-based therapy was associated with more grade 3/4 dizziness and constipation.

Keywords: carcinoma; meta-analysis; non-small cell lung; thalidomide.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Procedures used for trial selection
Fig. 2
Fig. 2
Comparison of overall survival between thalidomide and non-thalidomide based therapy
Fig. 3
Fig. 3
Comparison of two-year survival between thalidomide and non-thalidomide based therapy
Fig. 4
Fig. 4
Comparison of two-year survival between thalidomide and non-thalidomide based therapy
Fig. 5
Fig. 5
Comparison of tumor response between thalidomide and non-thalidomide based therapy
Fig. 6
Fig. 6
Summary of grade 3–4 hematological toxicity
Fig. 7
Fig. 7
Summary of grade 3–4 nonhematological toxicity
Fig. 8
Fig. 8
Funnel plot for comparison of tumor response
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. - PubMed
    1. Pérol M, Arpin D. Angiogenesis and lung cancer. Bull Cancer. 2007;94:S220–S31. Spec No. - PubMed
    1. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase iii study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage iii non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9. - PubMed
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8. - PubMed
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed

LinkOut - more resources